Nuvation Bio Inc. (NUVB)
NYSE
Price as at 10 Aug 2026, 12:25 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Nuvation Bio Inc. trades at USD6.60. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
13 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Stanley Druckenmiller, Duquesne Family Office LLC$25.79M · 0.5% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$13.38M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$11.51M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$11.29M · 0.0% of book
- Renaissance Technologies, RENAISSANCE TECHNOLOGIES LLC$7.65M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own NUVB?
13 of the institutions we track reported a position in NUVB in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its NUVB data?
Fundamentals for NUVB come from company filings and exchange data, as listed on NYSE; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 10 Aug 2026, 12:25 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for NUVB, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.